Last $69.45 USD
Change Today -0.82 / -1.17%
Volume 783.5K
ENDP On Other Exchanges
As of 1:47 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

endo international plc (ENDP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $82.16
52 Week Low
08/7/13 - $36.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

endo international plc (ENDP) Related Businessweek News

View More BusinessWeek News

endo international plc (ENDP) Details

Endo International plc, a specialty healthcare company, develops, manufactures, markets, and distributes branded pharmaceutical and generic products, and medical devices worldwide. It provides branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel to treat and manage pain and conditions in urology, endocrinology, and oncology. The company also offers non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets; and pharmaceutical products in the areas of ADHD, pain, urology, and allergy. In addition, it provides various medical devices comprising AMS 700 MS series, AMS 800 artificial urinary sphincters, GreenLight XPS laser systems, Elevate anterior and posterior pelvic floor repair systems, and Monarc subfascial hammock products in the areas of men’s and women’s health, and prostate health. The company’s products also include Aveed, an injectable testosterone preparation to treat male hypogonadism; and BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

3,371 Employees
Last Reported Date: 03/3/14
Founded in 1920

endo international plc (ENDP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $4.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $157.0K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $562.0K
Chief Operating Officer of Pharmaceuticals
Total Annual Compensation: $270.8K
Compensation as of Fiscal Year 2013.

endo international plc (ENDP) Key Developments

Endo International Plans to Issue Senior Notes in Private Offering

Endo International announced that it proposes to offer senior notes in a private offering. This private offering is being initiated by the company's wholly-owned subsidiaries, Endo Finance and Endo Finco, subject to market and customary conditions. These notes will be unsecured, unsubordinated obligations of Endo Finance and Endo Finco and will be guaranteed by Endo Limited, a wholly-owned subsidiary of Endo, and certain of Endo Limited's direct and indirect subsidiaries. Net proceeds from the proposed offering are expected to be used by Endo for general corporate purposes, acquisitions, including the acquisition of Dava Pharmaceuticals.

Endo Seeks Acquisitions

Endo International plc (NasdaqGS:ENDP) seeks acquisitions. Endo International plc announced that Endo Finance LLC and Endo Finco Inc., its wholly-owned subsidiaries, priced $750 million aggregate principal amount of 5.375% senior notes due January 2023 at an issue price of $1,000 per $1,000 principal amount in connection with their previously announced private offering. The notes will be unsecured, unsubordinated obligations of Endo Finance LLC and Endo Finco Inc. and will be guaranteed by Endo Limited, a wholly-owned subsidiary of Endo, and certain of Endo Limited's direct and indirect subsidiaries. Endo intends to use the net proceeds from the offering for general corporate purposes, which may include acquisitions, including the acquisition of Dava Pharmaceuticals, Inc.

Endo International Mulls Acquisitions

Endo International plc (NasdaqGS:ENDP) is looking for acquisitions. Rajiv De Silva, President and Chief executive Officer of Endo said, "With Endo's sharp focus, lean operating model and improved execution within our core businesses, strategic acquisitions will continue to play a key role in maximizing our growth potential and cash flow to drive future value for Endo shareholders".


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $69.47 USD -0.80

ENDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $146.06 USD +0.23
Dr Reddy's Laboratories Ltd 2,704 INR -29.75
Edwards Lifesciences Corp $85.26 USD -0.28
Hologic Inc $25.47 USD -0.12
Varian Medical Systems Inc $82.61 USD -4.91
View Industry Companies

Industry Analysis


Industry Average

Valuation ENDP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.6x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at